Sarepta Therapeutics Announces Proposed Public Offering of

Sarepta Therapeutics Announces Proposed Public Offering of Common
Stock 
CAMBRIDGE, MA -- (Marketwire) -- 12/12/12 --  Sarepta Therapeutics,
Inc. (NASDAQ: SRPT) today announced that it is offering to sell,
subject to market and other conditions, shares of its common stock in
an underwritten public offering. Sarepta also intends to grant the
underwriters a 30-day option to purchase from it up to an additional
15% of the shares of common stock offered in the public offering to
cover over-allotments, if any.  
Lazard Capital Markets LLC is acting as the sole book-running manager
of the offering.  
Sarepta intends to use the net proceeds from the offering for general
corporate purposes, including the continued development of eteplirsen
and other product candidates. 
A shelf registration statement on Form S-3 ASR relating to the public
offering of the shares of common stock described above was filed with
and automatically declared effective by the Securities and Exchange
Commission (SEC). A preliminary prospectus supplement relating to and
describing the terms of the offering will be filed with the SEC and
will be available on the SEC's web site at www.sec.gov. When
available, copies of the preliminary prospectus supplement relating
to these securities may also be obtained from the offices of Lazard
Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York,
NY, 10020 or via telephone at (800) 542-0970. 
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities of Sarepta, nor shall
there be any sale of securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction. 
Forward-Looking Statements and Information 
This press release contains statements that are forward-looking,
including the statements about the proposed public offering of
Sarepta's common stock, within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. These forward-looking statements involve risks and
uncertainties, many of which are beyond Sarepta's control, including
risk and uncertainties related to market conditions and satisfaction
of customary closing conditions related to the public offering. There
can be no assurance that Sarepta will be able to complete the public
offering on the anticipated terms, or at all. Risks and uncertainties
relating to Sarepta and its business can be found in the "Risk
Factors" section of Sarepta's most recent filing on Form 10-K, Form
10-Q and other SEC filings. Any forward-looking statement in this
press release represents Sarepta's views only as of the date of this
press release and should not be relied upon as representing its views
as of any subsequent date. Sarepta does not undertake any obligation
to publicly update its forward-looking statements based on events or
circumstances after the date hereof, except as required by applicable
law. 
Sarepta Investor and Media Contact: 
Erin Cox
425.354.5140
ecox@sareptatherapeutics.com